Healthcare ❯ Pharmaceuticals

Oncology

Drug Development Immunotherapy Cancer Treatments Drug Sales Immunology Cancer Drugs Product Revenue Prostate Cancer Drugs Targeted Therapy Pediatric Oncology

ADC Therapeutics Reports Q1 Revenue Growth, Tightens Costs, Eyes Lotus 5 Readout

Investors now look to the Lotus 5 data, a potential trigger for approvals followed by faster sales.

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Aktis Oncology Soars 24% in Nasdaq Debut After $318 Million IPO

AnaptysBio Seeks to Toss Tesaro Anticipatory‑Breach Claim in Jemperli Royalty Dispute

Biocon Moves to Fully Merge Biocon Biologics in $5.5 Billion Deal, Buys Out Viatris Stake

AnaptysBio and GSK’s Tesaro File Dueling Suits Over Jemperli License and Royalties

AbbVie Lifts 2025 Outlook and Dividend After Q3 Revenue Beat as Shares Fall

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

GSK Faces Revenue Decline Amid Vaccine Sales Slump

Pfizer and Merck Diverge in Q2 Performance Amid Revised Forecasts